Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest and confidence in the company’s performance and growth potential [1][2]. Group 1: Shareholding Changes - On October 24, southbound funds increased their holdings by 3.651 million shares, representing a 0.25% change [2]. - Over the past five trading days, there were four days of net increases, totaling 3.666 million shares [1]. - In the last 20 trading days, there were 14 days of net increases, amounting to 36.725 million shares [1]. Group 2: Current Shareholding Status - As of October 24, southbound funds hold a total of 1.445 billion shares of Jinxin Reproductive Medicine, which constitutes 52.39% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2]. - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment [2]. - The company operates mainly in China and the United States [2].
锦欣生殖（01951.HK）：10月24日南向资金增持365.1万股